REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Five-membered Hetero Ring Containing At Least One Nitrogen Ring Atom (e.g., 1,2,3-triazoles, Etc.) > 1,3,4-thiadiazoles (including Hydrogenated) > Chalcogen Bonded Directly To Ring Carbon Of The Thiazole Ring Chalcogen Bonded Directly To Ring Carbon Of The Thiazole RingChalcogen Bonded Directly To Ring Carbon Of The Thiazole Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027197 - Pharmaceutical composition and method for the treatment of diseases using hmg-coa reductase inhibitors and insulin secretion enhancers or sensitizers The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt ... 01/11/07 - 20070010566 - Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents as welt as to their production and to their use as inhibitors of the polo-like kinase (Plk) for treating various diseases, as welt as to intermediate products for the production of the compounds according to the invention. ... 01/11/07 - 20070010565 - New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents to their production and to their use as inhibitors of the polo-like kinase (Plk) for treating various diseases. ... 12/21/06 - 20060287373 - Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibit cathepsins K, L, S and B. These compounds are ... 12/21/06 - 20060287372 - Pharmaceutical preparations containing thiazolidinediones showing new therapeutic indications The present invention refers to new therapeutic applications of pharmaceutical formulations containing, as active principles, thiazolidinediones. ... 12/14/06 - 20060281798 - Methods of using thiazolidinedithione derivatives Methods of using thiazolidinedithione derivatives to treat cancer, neurodegenerative disease, diabetes, renal disease or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed. ... 12/07/06 - 20060276520 - Rhodanine derivatives and pharmaceutical compositions containing them This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as ... 11/30/06 - 20060270721 - Ep4 receptor agonist, compositions and methods thereof This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of ... 11/30/06 - 20060270720 - Iminothiazolidinone derivatives as sfrp-1 antagonists which are inhibitors of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis. ... 11/23/06 - 20060264484 - Fc receptor modulating compounds and compositions The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc ... 11/02/06 - 20060247285 - Novel heterocyclic diphenyl ethers The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood ... 10/19/06 - 20060235062 - Novel heterocyclic analogs of diphenylethylene compounds Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment ... 10/05/06 - 20060223871 - Thiophene-and thiazolesulfonamides as antineoplastic agents and antineoplastic methods. ... 10/05/06 - 20060223870 - Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided. ... 09/28/06 - 20060217427 - Cytoskeletal active compounds, compositions and use The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases ... 09/21/06 - 20060211749 - Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and/or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, ... 09/21/06 - 20060211748 - Sulphydryl compounds in combination with sulpha compounds The present invention discloses various compositions and methods for co-administration of one or more sulfa compounds or pharmaceutically acceptable salts thereof, and one or more sulphydryl compounds in the treatment or prevention of disease, wherein the disease has in whole or part microbial and/or inflammatory origins. ... 08/17/06 - 20060183782 - Methods of using thiazolidine derivatives to treat cancer or inflammation Methods of using thiazolidine derivatives of formula (I) to treat cancer, inflammation, or other disorders related to the activities of protein phosphatases PTPN12 or PTPN2 in a mammal are disclosed. Pharmaceutical compositions containing such derivatives are disclosed. ... 07/20/06 - 20060160868 - 3-phenylpropionic acid derivatives The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or ... 07/20/06 - 20060160867 - Methods for modulating ppar biological activity for the treatment of diseases caused by mutations in the cftr gene This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPARγ, PPARα, and PPARδ agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds. ... 06/29/06 - 20060142357 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a ... 06/29/06 - 20060142356 - Novel therapeutic method and compositions for topical administration According to the invention there is provided a pharmaceutical composition suitable for topical administration to the skin which comprises farglitazar, or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier and its use in the treatment of skin conditions. ... 06/15/06 - 20060128771 - Method of treating acne A method of selectively enhancing photothermal sebaceous gland disruption and treatment of acne is disclosed. The method provides for alleviation of the acne symptoms as well as preventing acne recurrence and new acne from occurring. ... 06/08/06 - 20060122244 - Use of compounds The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of ... 06/08/06 - 20060122243 - Antiallergic wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring ... 05/25/06 - 20060111409 - Medicament for treatment of diabetes wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring ... 05/18/06 - 20060106077 - Pin1-modulating compounds and methods of use thereof The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. ... 05/18/06 - 20060106076 - Compositions and methods for the non-invasive treatment of uterine fibroid cells The proliferation of uterine fibroid leiomyoma cells is inhibited by certain Fibroid Cell Growth Inhibitor (FGI) agents. Pharmacological doses of FGI agents can be made high enough to not only inhibit proliferation, but to cause cell death. Non-invasive or minimally invasive, non-systemic delivery methods deliver the FGI agent to the ... 05/11/06 - 20060100257 - Inhibitors against the activation of ap-1 and nfat wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring ... 04/20/06 - 20060084688 - Aromatic sulfone hydroxamic acid metalloprotease inhibitor A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a ... 03/30/06 - 20060069137 - Novel process for ezetimibe intermediate The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]4-phenyl-2-oxazolidinone is reduced with (−)-DIP chloride to obtain 3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]4-phenyl-2-oxazolidinone. ... 03/23/06 - 20060063818 - Hydantoin derivatives and deren verwendung als tace inhibitoren Hydantoin derivatives of Formula (1) that are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α Converting Enzyme (TACE). ... 03/09/06 - 20060052425 - Method for modulating microbial quorum sensing The present invention provides compositions and methods for modulating bacterial quorum sensing using antagonist or agonist compounds. Further, the present invention provides methods of treating or preventing microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens. ... 03/09/06 - 20060052424 - Lactacystin analogs Compounds related to lactacystin and lactacystin β-lactone, pharmaceutical compositions containing the compounds, and methods of use. ... 03/02/06 - 20060047000 - Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is ... 02/23/06 - 20060040998 - Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed. ... 01/19/06 - 20060014812 - Use of estrogen related receptor-modulating aryl ethers Therapeutic methods of using certain heterocyclic arylidene aryl ether compounds for treating diseases or disorders mediated through modulation of estrogen related receptor alpha are described. ... 01/19/06 - 20060014811 - Medicament for treatment of cancer wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is {circle around (1)} a fused polycyclic heteroaryl group wherein the ring ... 12/29/05 - 20050288342 - Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides and processes for the production thereof. Pharmaceutical preparations containing these compounds and the use of these compounds for the production of pharmaceutical preparations and in related treatment methods. ... // - 5-aminomethyl-1H-pyrrole-2-carboxylic acid amide compounds corresponding to formula I - ... 12/29/05 - 20050288341 - Novel diphenyl ether derivatives Novel diphenyl ether derivatives are provided that exhibit activity useful for reducing glucose, cholesterol, and/or triglyceride levels in plasma, and for treatment of obesity, inflammation, immunological diseases, autoimmune diseases, diabetes and disorders associated with insulin resistance. ... 12/22/05 - 20050282876 - Inhibitors of impdh enzyme The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents ... 11/24/05 - 20050261349 - Medicine for prevention or treatment of diabetes The present invention provides a medicine for preventing or treating a diabetes, which includes 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, and glibenclamide as active ingredients. The present invention provides a method for preventing or treating a diabetes, which includes administering 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, ... 11/17/05 - 20050256176 - Sulphonamide derivatives and their use as tace inhibitors Sulphonamide derivatives that are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α Converting Enzyme (TACE). ... 10/06/05 - 20050222225 - Use of compounds for increasing spermatozoa motility The invention relates to a process for the improvement of spermatozoa fertilization activity, in particular for the increase of spermatozoa motility, by using a compound of formula (I). The invention further relates to uses and methods of compounds of formula (I) in infertility and assisted reproduction techniques (ART) as well ... 09/29/05 - 20050215607 - Drug composition for prevention or inhibition of advance of diabetic complication The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to prevent or inhibit the progression of diabetic complication, which comprises 5 to 45 mg, as a single ... 09/29/05 - 20050215606 - Use of parathyroid hormone-related protein(pthrp) in the diagnosis and treatment of chronic lung disease and other pathologies This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health”, and “disease”, and can be used to predict lung disease in patients at ... 09/29/05 - 20050215605 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C1-C6 Alkyl cycloalkyl, C1-C6-alkyl heteroaryl, aryl, heteroaryl, ... 09/22/05 - 20050209292 - Cancer therapy This invention relates to a method of regulating the cell cycle and treating cancer with a peroxisome proliferator-activated receptor γ agonist and a mevalonate pathway inhibitor or a mevalonate antagonist. ... 08/11/05 - 20050176787 - Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth Use of thiazolidinedione derivatives for the preparation of medicaments for inhibiting or reducing tumour growth or metastases, alone or in combination with an RXR agonist or well-known antitumour agent. ... 07/28/05 - 20050165072 - Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as ... 07/21/05 - 20050159463 - Indole derivatives The invention relates to 1-(R1)-2-(R2)-3-(Y-X-NH-A- or Z-A-)-4,5,6,7-R)0-4-indoles, and their acid addition salts where the compounds are basic, wherein A is C1-4 alkylene, X is >CH2, >C=O or >C=S, and the other symbols have various defined values, and to pharmaceutical, skin-protective and cosmetic compositions which comprise them. ... 06/23/05 - 20050137238 - Biaromatic ligand activators of ppargamma receptors and are well suited, inter alia, for regulating and/or restoring skin lipid metabolism, for treating a wide variety of dermatological afflictions, and for preventing and/or treating the signs of aging and/or dry skin. ... ### FreshPatents.com Support |